Dublin, Jan. 23, 2017 -- Research and Markets has announced the addition of the "Vascular Dementia Forecast in 13 Major Markets 2017-2027" report to their offering.
Vascular Dementia (VaD) is the second most common form of dementia after Alzheimer disease. It is also known as multi-infarct dementia (MID) and vascular cognitive impairment (VCI), and is caused by issues with blood supply to the brain, typically caused by a series of minor strokes.
This report provides the current prevalent population for Vascular Dementia across 13 Major Markets (USA, Canada, France, Germany, Italy, Spain, United Kingdom, Brazil, Japan, India, China, Republic of Korea and Russian Federation) and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Vascular Dementia have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for Vascular Dementia include:
- Stroke
- Diabetes
- Heart disease
- Sleep apnoea (linked with hypertension)
- Other dementias
Key Topics Covered:
1. Introduction
2. Cause of the Disease
3. Risk Factors & Prevention
4. Diagnosis of the Disease
5. Variation by Geography/Ethnicity
6. Disease Prognosis & Clinical Course
7. Key comorbid conditions/Features associated with the disease
8. Methodology for quantification of patient numbers
9. Top-line prevalence for Vascular Dementia
10. Features of Vascular Dementia patients
11. Significant Comorbid Conditions associated with Vascular Dementia
12. Abbreviations used in the report
13. Patient-Based Offering
14. Online Pricing Data and Platforms
15. References
16. Appendix
For more information about this report visit http://www.researchandmarkets.com/research/6nnp8k/vascular_dementia
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs


American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 



